{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:21:20Z","timestamp":1755037280353,"version":"3.32.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening adverse drug reaction with numerous diagnostic challenges. Diagnosis of HIT begins with 4T score clinical assessment, followed by laboratory testing for those not deemed low risk. Laboratory testing for HIT includes screening [enzyme-linked immunosorbent assay (ELISA)] and confirmatory [serotonin release assay (SRA)] assays, wherein SRA testing can be pursued following a positive ELISA result. These tests aid diagnosis of HIT, but also introduce interpretive challenges, additional costs, and delays in clinical intervention.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective review of 1011 HIT ELISA and 169 SRA tests performed over 5 years was conducted. ELISA percent inhibition and ELISA low-heparin optical density (OD) were evaluated for positive predictive value (PPV). Based on these findings, HIT ELISA reporting and management algorithm changes were implemented and metrics compared for 5 months pre- and post-intervention to assess intervention success.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Equivocal and positive HIT ELISA interpretation showed poor PPV based on percent inhibition (0.20 and 0.32, respectively). However, rising low-heparin OD correlated with increasing PPV (PPV of 0.00 for OD values 0.40\u20131.00, 0.29 for values 1.00\u20131.99, and 0.91 for values &amp;gt;2.00). Data-driven intervention decreased ELISA positivity rates (13% to 5%), decreased rates of SRA confirmatory testing overall (13% to 9%), decreased SRA testing rates for patients with non-negative ELISAs (78% to 43%), and increased heparin resumption (20% to 57%). Hematology consults remained relatively stable (78% and 86%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Low-heparin OD-based HIT ELISA interpretation yielded enhanced PPV compared with percent inhibition-based interpretation. Implementation of data-driven changes improved testing stewardship and clinical management for patients with non-negative ELISAs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jalm\/jfae131","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T09:49:48Z","timestamp":1735897788000},"page":"26-35","source":"Crossref","is-referenced-by-count":1,"title":["Increasing the Diagnostic Utility of Heparin-Induced Thrombocytopenia (HIT) Testing: An Academic Medical Center\u2019s Utilization Analysis and Intervention"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-1938","authenticated-orcid":false,"given":"Meredith G","family":"Parsons","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Iowa Health Care , Iowa City, IA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan A","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, University of Iowa Health Care , Iowa City, IA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa Health Care , Iowa City, IA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-5937","authenticated-orcid":false,"given":"Anna E","family":"Merrill","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa Health Care , Iowa City, IA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"2025010309490141200_jfae131-B1","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"key":"2025010309490141200_jfae131-B2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0038-1656329","article-title":"Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia","volume":"68","author":"Amiral","year":"1992","journal-title":"Thromb Haemost"},{"key":"2025010309490141200_jfae131-B3","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N Engl J Med"},{"key":"2025010309490141200_jfae131-B4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2141.1998.00750.x","article-title":"High incidence of anti-heparin\/platelet factor 4 antibodies after cardiopulmonary bypass surgery","volume":"101","author":"Trossaert","year":"1998","journal-title":"Br J Haematol"},{"key":"2025010309490141200_jfae131-B5","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1161\/01.CIR.99.19.2530","article-title":"Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia","volume":"99","author":"Pouplard","year":"1999","journal-title":"Circulation"},{"key":"2025010309490141200_jfae131-B6","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.06-2109","article-title":"The incidence of recognized heparin-induced thrombocytopenia in a large tertiary care, teaching hospital","volume":"131","author":"Smythe","year":"2007","journal-title":"Chest"},{"key":"2025010309490141200_jfae131-B7","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood.V96.5.1703","article-title":"Impact of the patient population on the risk for heparin-induced thrombocytopenia","volume":"96","author":"Warkentin","year":"2000","journal-title":"Blood"},{"key":"2025010309490141200_jfae131-B8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2006.01787.x","article-title":"Evaluation of pretest clinical score (4T\u2019s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings","volume":"4","author":"Lo","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2025010309490141200_jfae131-B9","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1182\/blood-2012-07-443051","article-title":"Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis","volume":"120","author":"Cuker","year":"2012","journal-title":"Blood"},{"key":"2025010309490141200_jfae131-B10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2014-12-618165","article-title":"Combination of 4Ts score and PF4\/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study","volume":"126","author":"Linkins","year":"2015","journal-title":"Blood"},{"key":"2025010309490141200_jfae131-B11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11239-019-02011-8","article-title":"Pharmacist involvement in clinical assessment and laboratory testing for heparin-induced thrombocytopenia","volume":"50","author":"Condon","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"2025010309490141200_jfae131-B12","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2010-01-262659","article-title":"Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia","volume":"116","author":"Whitlatch","year":"2010","journal-title":"Blood"},{"key":"2025010309490141200_jfae131-B13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.thromres.2011.05.003","article-title":"Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4\/heparin enzyme-immunoassay","volume":"128","author":"Althaus","year":"2011","journal-title":"Thromb Res"},{"key":"2025010309490141200_jfae131-B14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2015-07-661215","article-title":"Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis","volume":"127","author":"Nagler","year":"2016","journal-title":"Blood"},{"key":"2025010309490141200_jfae131-B15","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/ajh.23248","article-title":"Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia","volume":"87","author":"McFarland","year":"2012","journal-title":"Am J Hematol"},{"key":"2025010309490141200_jfae131-B16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1538-7836.2005.01698.x","article-title":"No significant improvement in diagnostic specificity of an anti-PF4\/polyanion immunoassay with use of high heparin confirmatory procedure","volume":"4","author":"Warkentin","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"2025010309490141200_jfae131-B17","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2021-154504","article-title":"Diagnostic utility of high dose heparin confirmation step in heparin induced thrombocytopenia ELISA assay","volume":"138","author":"Saadalla","year":"2021","journal-title":"Blood"},{"key":"2025010309490141200_jfae131-B18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s11239-016-1408-6","article-title":"Treatment of heparin-induced thrombocytopenia before and after the implementation of a hemostatic and antithrombotic stewardship program","volume":"42","author":"Ritchie","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"2025010309490141200_jfae131-B19","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/08971900221116185","article-title":"The impact of an antithrombotic stewardship program on heparin-induced thrombocytopenia management","volume":"36","author":"Lee","year":"2023","journal-title":"J Pharm Pract"},{"key":"2025010309490141200_jfae131-B20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11239-015-1189-3","article-title":"Implementation of a hemostatic and antithrombotic stewardship program","volume":"40","author":"Reardon","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"Suppl 1","key":"2025010309490141200_jfae131-B21","first-page":"4639","article-title":"Striving to HIT the bullseye when diagnosing heparin-induced thrombocytopenia","volume":"130","author":"Schaffner","year":"2017","journal-title":"Blood"},{"key":"2025010309490141200_jfae131-B22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/ajcp\/aqx078","article-title":"Evaluation of a reflex testing algorithm for suspected heparin-induced thrombocytopenia","volume":"148","author":"Vanderbilt","year":"2017","journal-title":"Am J Clin Pathol"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/10\/1\/26\/61265809\/jfae131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/10\/1\/26\/61265809\/jfae131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T09:49:56Z","timestamp":1735897796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/10\/1\/26\/7931432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,3]]},"published-print":{"date-parts":[[2025,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfae131","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]}}}